Abstract:Abstract The combination antiretroviral therapy (cART) effectively suppresses HIV replication and enables HIV-infected individuals to live long-productive lives. However, the persistence of HIV reservoir cells with latent or lowreplicating HIV in patients under cART make HIV infection an incurable disease. Plasmacytoid dendritic cells (pDCs) suppress HIV replication through secreting type I interferon (IFN-I). We have reported that pDCs play a major pathogenic role in chronic HIV infection in vivo. In this study, we discovered that pDCs-depletion during cART completely resolved HIV immune pathogenesis and rescued anti-HIV T cell response in humanized mice. Importantly, HIV reservoirs (total cell-associated HIV DNA as well as cells with replication-competent HIV virus) are reduced by pDCs-depletion. We showed that HIV infection induced IDO expression in monocytes and DC via pDC-dependent mechanism. Interestingly, IDO inhibition during cART similarly resolved HIV immune pathogenesis and rescued anti-HIV T cell response, correlated with reduced HIV reservoirs in humanized mice in vivo. Finally, we proved that pDCs depletion and IDO inhibition acted through the same pathway to reverse HIV pathogenesis. We conclude that pDCs persistently activated by HIV lead to IDO expression that induces host immune exhaustion, contributing to HIV reservoirs persistence during effective cART. Strategies to disrupt the pDC-IDO axis will provide novel opportunities to achieve HIV-1 functional cure therapy.

HIV-1 Vpr Degrades TET2 to Suppress IRF7 and Interferon Expression in Plasmacytoid Dendritic Cells

Vpr Targets TET2 for Degradation by CRL4VprBP E3 Ligase to Sustain IL-6 Expression and Enhance HIV-1 Replication

Vpr driving DNA methylation variation of CD4 + T cells in HIV-1 infection

Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages

Interaction of Virion Protein Vpr of Human Immunodeficiency Virus Type 1 with Cellular Transcription Factor Sp1 and trans-Activation of Viral Long Terminal Repeat

The Hiv-1 Vif Protein Mediates Degradation Of Vpr And Reduces Vpr-Induced Cell Cycle Arrest

HIV-1 Vpr Induces Interferon-Stimulated Genes in Human Monocyte-Derived Macrophages

HIV-1 Vpr combats the PU.1-driven antiviral response in primary human macrophages

HIV-1 Vpr suppresses the cytomegalovirus promoter in a CRL4(DCAF1) E3 ligase independent manner.

HIV reprograms host m6Am RNA methylome by viral Vpr protein-mediated degradation of PCIF1

HIV-1 Vpr Functions in Primary CD4+ T Cells

HIV-1 Vpr Stimulates NF-κB and AP-1 Signaling by Activating TAK1

HIV-1 Vpr Protein Upregulates Microrna-210-5p Expression to Induce G2 Arrest by Targeting TGIF2

Plasmacytoid Dendritic Cells Impair HIV-specific CD8 T Cells to Maintain HIV-1 Reservoir Persistence During Chronic HIV Infection under Cart

HIV-1 Vpr Activates Both Canonical and Noncanonical NF-κB Pathway by Enhancing the Phosphorylation of IKKα/β.

Plasmacytoid Dendritic Cells Prime Antiviral T Cells During Acute Hiv-1 Infection But Deplete And Impair Anti-Viral T Cells During Chronic Hiv-1 Infection

HIV-1 Vif Suppresses Antiviral Immunity by Targeting STING

Plasmacytoid Dendritic Cells Impair Anti-HIV Immunity and HIV-1 Persistence During Antiretroviral Therapy Via IDO-Dependent Mechanisms

Plasmacytoid Dendritic Cells Contribute to HIV Diseases and Viral Persistence Via IDO-dependent Mechanisms

Vpr expression abolishes the capacity of HIV-1 infected cells to repair uracilated DNA

HIV Vpr activates a nucleolar-specific ATR pathway to degrade the nucleolar stress sensor CCDC137